Goserelin EP Impurity I is a structurally related variant produced during goserelin synthesis. Differences in protecting-group removal or residue configuration influence retention time and secondary structure. Researchers employ it to validate sensitivity of analytical workflows. Applications include impurity profiling, stability studies, and peptide-route refinement.
CAT No: Z10-101-236
Synonyms/Alias:Endo-8a,8b-di-L-proline-goserelin; (S)-N-((6S,9S,12R,15S,18S,21S,24S)-21-((1H-Indol-3-yl)methyl)-1-amino-12-(tert-butoxymethyl)-6-((S)-2-((S)-2-((S)-2-(2-carbamoylhydrazine-1-carbonyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carbonyl)-15-(4-hydroxybenzyl)-18-(hydroxymethyl)-25-(1H-imidazol-4-yl)-1-imino-9-isobutyl-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazapentacosan-24-yl)-5-oxopyrrolidine-2-carboxamide;
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More